Viridian Therapeutics : J.P. Morgan Conference Podium Presentation

J.P. Morgan 41st Annual Healthcare Conference

January 9, 2023

Cautionary note regarding forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements include, without limitation, statements regarding our expectations, strategies, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: the efficacy and safety of VRDN-001,VRDN-002, and VRDN-003 for the treatment of TED; the relationship between the results from the positive data from the ongoing Phase 1/2 clinical trial of VRDN-001 and the first-in-human Phase 1 clinical trial of VRDN-002 and results or future of ongoing clinical trials; the timing, progress and plans for our ongoing or future research and clinical development programs; trial protocols for ongoing clinical trials, including the clinical trials for VRDN-001,VRDN-002, and VRDN-003; expectations regarding the timing for data, including the expected timing of additional data from the ongoing Phase 1/2 clinical trial of VRDN-001 and the first-in-human Phase 1 clinical trial of VRDN- 002; uncertainty and potential delays related to clinical drug development; the duration and impact of regulatory delays in our clinical programs; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates, including VRDN-001,VRDN-002, and VRDN-003; manufacturing risks; our ability to develop a subcutaneous formulation; competition from other therapies or products; other matters that could affect the sufficiency of existing cash, cash equivalents and short-term investments to fund operations; our financial position and its projected cash runway; our future operating results and financial performance; the clinical utility of our therapeutic candidates and our intellectual property position; the timing of pre-clinical and clinical trial activities and reporting results from same; the effects from the COVID- 19 pandemic on our research, development and business activities and operating results, including those risks set forth under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 11, 2022 and other subsequent disclosure documents filed with the SEC. The forward-looking statements in this presentation represent our views as of the date of this presentation. Neither we, nor our affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this presentation.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

2

Our mission: best-in-class for patients with rare diseases

Founded in 2020 in Waltham, MA 90+ employees market capitalization thyroid eye disease runway into 2H25

Viridian's discovery engine leverages core expertise in antibody discovery and engineering

Strategy	1			2			3
First entrant	Significant	First entrant
	validates a new		market	leaves room for
	mechanism of	opportunity;	improvement
	action	serious disease
			with limited
			competition

4			5
Viridian identifies	Viridian rapidly
and engineers	advances
potential best-in-		selected
class antibodies	antibodies to
			patients

4

Viridian development pipeline

PRECLINCAL	PHASE 1

Thyroid Eye Disease (TED)

VRDN-001 IV	THRIVE Phase 3
	Phase 1/2
	Ongoing Phase 1/2

VRDN-002 SC	Phase 1/2 POC
VRDN-003 SC	IND enabling
Autoimmune & Rare Diseases
VRDN-004	Rare Disease
VRDN-005	Autoimmune
VRDN-006	Autoimmune

PHASE 2	PHASE 3

Active TED

Active TED

Chronic TED

Active TED

5

VRDN-001,-002,-003,-004,-005, and -006 are investigational therapies that are not approved for any use in any country.